A pilot evaluation of the pharmacokinetics, efficacy and safety of switching from efavirenz to maraviroc administered at 600mg then 300mg twice-daily in patients suppressed on an efavirenz-containing regimen as initial therapy - Pharmacokinetics of switching from efavirenz to maraviroc

未提供0 个研究点目标入组 12 人开始时间: 2009年10月23日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•1.The ability to understand and sign a written informed consent form, prior to participation in any screening procedure and must be willing to comply with all study requirements.
•2.Males or non-pregnant, non-lactating females.
•3.Between 18 to 65 years, inclusive.
•4.Documented HIV-1 infection of at least 6 months duration.
•5.Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study.
•6.CD4 count > 50 cells/mm3 at screening (Note retesting of screening CD4 count is allowed).
•7.Receiving a first-line antiretroviral regimen including two NRTI with efavirenz, without any history of virological failure and agrees to remain on this regimen unless change is clinically indicated (history of drug switches is allowed only if the reason was tolerability/toxicity/convenience of dosing).
•8.Viral load <50 copies/ml at screening and for at least 12 weeks prior to screening visit (Note retesting of screening viral load is allowed).
•9.R5-tropic virus as determined by genotypic assay performed at screening visit.
•10.No medical, psychiatric or substance misuse disorders felt by the investigator to impact on the subject’s ability to participate in the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Dual, mixed or X4-tropic virus on geno2pheno tropism sample
•2.HIV-2 co-infection
•3.Any prior CCR5 antagonists
•4.Any genotypic resistance to NNRTI or backbone NRTI on screening or prior tests (or likely from treatment history)
•5.Disallowed concomitant medication as per the SPC for Truvada, Kivexa or Celsentri (see section 5.1.1)
•6.Any medical condition or psychiatric illness that may, in the opinion of the investigator, affect patient safety or the integrity of the results
•7.ALT or AST elevation greater than five times the upper limit of normal
•8.Estimated GFR (MDRD) less than 50ml/min
•9.Hepatitis B or C co-infection (defined as positive hepatitis B surface antigen or detectable hepatitis C RNA; hepatitis C antibody positive individuals with undetectable RNA will be eligible for inclusion)

发起方

未提供